Optimal PharmacoTherapy and Invasive Management of Atrial Fibrillation in Patients With Heart Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1050 participants.

Also called NCT07238452

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,050 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07238452
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07238452. Randomized; single masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2032-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimal PharmacoTherapy and Invasive Management of Atrial Fibrillation in Patients With Heart Failure
Acronym
OPTIMal AF-HF
Condition
Atrial Fibrillation (AF)
Intervention (Device)
Pulmonary Vein Isolation
Intervention (Drug)
Pharmacological Rate Control
Lead sponsor
University of British Columbia (class: other)

Record details

Record id
cardio:ct-nct07238452
Content hash
b6ebb29e4b0f49bc0506ba679858cf9eeca2cf39ed43be9ee5aa902c06e21660